Fundamental Analysis of Akero Therapeutics Inc - Growth / Value Index


AKRO - Valuation Highlights

Valuation Analysis

   Tremendous increasing in Book Value last 3 year
   Tsr Value Index - Very Poor Score of 5.00
   Price to Book Ratio of 457.31 suggesting that it is very expensive
Valuation Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Price to Earning -1445.58 -8.75 -26.28 %
Price to Book 448.75 1.96 -17.74 % 1.40
Price to Sales 912505 0 0 %
Enterprise Value to EBITDA Multiple -5.96 -7.16 -48.48 %


AKRO - Profitability Highlights

Profitability Analysis

   Tsr Profitability Index - Very Poor Score of 5.00
   Piotroski F Score - Very Poor Value of 1.0
   Very Low Dividend Yield of 0 %
   Negative Net profit for last two years
   Company Net profit is Negative for last 5 Quarters
   In the last three years, the company has given poor Net Margin
   In the last three years, the company has given poor Returns on Equity
   In the last three years, the company has given poor Returns on Assets
Profitability Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Return On Equity -31.04 -22.35 34.86 % -6.30
Return On Asset -28.54 -20.62 34.38 % -5.85
Net Profit Margin -63123.94 0 0 % 0
Operating Profit Margin -71855.99 0 0 % 0
EBITDA Margin -69091.20 0 0 % 0


Highlights
Market Cap1377.49 M
Enterprise Value1168.50 M
Price/Book TTM448.75
Outstanding Share69151.00 K
Float/ Outstanding Share79.20%
Dividend Yield0 %
Share Holding
Guru Numbers
Price/Graham No0
Peter Lynch Ratio0
Piotroski F Score1.00
Altman Z Score17.45
Sloan Ratio0.0045
Peter Lynch Fair Value0


AKRO - Growth Highlights

Growth Analysis

   Annual sales of the company is increased for three years in a row
   Steady increase in Total Assets for last 3 Years
   Tsr Growth Index - Very Poor Score of 18.75
   Quarterly sales in last 5 Quarter is trending down
   Annual sales in last 3 years is trending down
   Operating Cash Flow decreasing for last 3 year
Growth Key Fields
Field TTM YoY Growth QoQ Growth
Revenue 284000 % 100.00 %
Gross Profit 207000 100.03 % 100.35 %
EBITDA -196219.00 K 5.18 % 3.10 %
Net Profit -179272.00 K 6.78 % 3.34 %
EPS -0.0138 20.81 % NA


AKRO - Stability Highlights

Stability Analysis

   Altman Z Score of 17.80 suggests good Stability
   Cash ratio of 28.75
   Company financial liquidity has improved
   Company is unable to generate enough free cash to support the business.
   Interest Coverage of -45.66
Stability Key Ratios
Ratio Latest FY Yoy Change MRQ
Debt to Equity Ratio 0.0471 55.97 % 0.0419
Cash Ratio 28.75 56.13 %
Quick Ratio 0 0 % 30.12
Shareholders Equity 92.25 0.728 %
Debt to EBITDA -0.216 -143.07 %


Historical Valuation Ratios of Akero Therapeutics Inc

Historical Valuation Ratios
Loading ...

Historical Profitability Ratios of Akero Therapeutics Inc

Historical Profitability Ratios
Loading ...

Historical Efficiency Ratios of Akero Therapeutics Inc

Historical Efficiency Ratios
Loading ...

Historical Solvency Ratios of Akero Therapeutics Inc

Historical Solvency Ratios
Loading ...


Note : All Data Generated at the End of Trading Hours (EOD Data)